To evaluate milrinone's impact on pediatric cardiac function, focusing on its specific role as
an inotrope and lusitrope, while considering its systemic and pulmonary vasodilatory effects …

BACKGROUND Low cardiac output syndrome (LCOS) after congenital cardiac surgery has
an incidence of up to 25%. Preventing and treating LCOS is of pivotal importance as LCOS …

Objective Both milrinone and levosimendan have been used in patients undergoing surgical
closure of ventricular septal defects (VSD) with pulmonary artery hypertension (PAH); …

Background The potential risks associated with the use of levosimendan in the pediatric
population has not been systematically evaluated. This study aimed to review the available …

Introduction Low cardiac output syndrome (LCOS) is a significant cause of morbidity and the
leading cause of mortality after pediatric cardiac surgery. Levosimendan has been shown …

Anti-hypotensive treatment, which includes dopamine, dobutamine, epinephrine,
norepinephrine, milrinone, vasopressin, terlipressin, levosimendan, and glucocorticoids, is a …

Background Children with congenital heart disease (CHD) are easily complicated by severe
pneumonia and heart failure. We aimed to conduct a meta-analysis to evaluate the effects …

Background: Various inotropes and inodilators have been utilized to treat low cardiac output
syndrome after the arterial switch operation. The use of levosimendan, a calcium sensitizer …

Левосимендан относят к классу препаратов-сенситизаторов кальция, который
проявляет свои положительные инотропные эффекты за счет увеличения сродства …

Background: Congenital heart disease (CHD) is a prevalent pediatric heart condition, often
complicated by severe pneumonia. Milrinone, a second-generation phosphodiesterase …